BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 12694669)

  • 21. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
    Rothenberg ML; Ozols RF; Glatstein E; Steinberg SM; Reed E; Young RC
    J Clin Oncol; 1992 May; 10(5):727-34. PubMed ID: 1569445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemotherapy, early surgical reassessment, and hyperfractionated abdominal radiotherapy in stage III ovarian cancer: results of a gynecologic oncology group study.
    Randall ME; Barrett RJ; Spirtos NM; Chalas E; Homesley HD; Lentz SL; Hanna M
    Int J Radiat Oncol Biol Phys; 1996 Jan; 34(1):139-47. PubMed ID: 12118543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
    Gershenson DM; Sun CC; Lu KH; Coleman RL; Sood AK; Malpica A; Deavers MT; Silva EG; Bodurka DC
    Obstet Gynecol; 2006 Aug; 108(2):361-8. PubMed ID: 16880307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
    Fader AN; von Gruenigen V; Gibbons H; Abushahin F; Starks D; Markman M; Belinson J; Rose P
    Gynecol Oncol; 2008 Apr; 109(1):33-8. PubMed ID: 18261784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC).
    Price FV; Chambers SK; Carcangiu ML; Kohorn EI; Schwartz PE; Chambers JT
    Gynecol Oncol; 1993 Dec; 51(3):383-9. PubMed ID: 8112650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel].
    Nishio S; Kawata T; Harada C; Kawagoe H; Fujiyoshi K; Ishimatsu J; Tsunawaki A; Sugiyama T; Kamura T
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):309-12. PubMed ID: 11865640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).
    Fields AL; Einstein MH; Novetsky AP; Gebb J; Goldberg GL
    Gynecol Oncol; 2008 Jan; 108(1):201-6. PubMed ID: 17997145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
    Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
    J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
    Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
    Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study.
    Young RC; Brady MF; Nieberg RK; Long HJ; Mayer AR; Lentz SS; Hurteau J; Alberts DS
    J Clin Oncol; 2003 Dec; 21(23):4350-5. PubMed ID: 14645424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
    Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
    Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
    Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
    Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
    Marth C; Tropé C; Vergote IB; Kristensen GB
    Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Wils J; van Geuns H
    Am J Clin Oncol; 1989 Jun; 12(3):251-4. PubMed ID: 2658540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.